Bridge Biotherapeutics rebrands, pivots to digital assets

Bridge Biotherapeutics has changed its name to Parataxis Korea and is pivoting to focus on its digital asset treasury business, DealSite reported. The company, once a promising biotech drug developer known for a major technology transfer deal, underwent a sale of management rights and a business restructuring after the failure of its core pipeline.